

# N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021

<https://marketpublishers.com/r/N6B71FA45F89EN.html>

Date: June 2021

Pages: 60

Price: US\$ 3,500.00 (Single User License)

ID: N6B71FA45F89EN

## Abstracts

N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021

### SUMMARY

According to the recently published report 'N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021'; N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) pipeline Target constitutes close to 8 molecules.

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - N-sulphoglucosamine sulphohydrolase is an enzyme encoded by the SGSH gene. This enzyme is involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccharidosis III.

The report 'N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021' outlays comprehensive information on the N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical

and Discovery stages are 1, 2, 4 and 1 respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) and Alzheimer's Disease.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1)

The report reviews N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics and enlists all their major and minor projects

The report assesses N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or

EC 3.10.1.1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for N Sulphoglucosamine Sulphohydrolase (Sulphoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding N Sulphoglucosamine Sulphohydrolase (Sulphoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Overview

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Companies Involved in Therapeutics Development

Abeona Therapeutics Inc

Amicus Therapeutics Inc

ArmaGen Inc

Denali Therapeutics Inc

Esteve Pharmaceuticals SA

JCR Pharmaceuticals Co Ltd

Lysogene SAS

Tega Therapeutics Inc

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Drug Profiles

AGT-184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EGT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Replace Sulphamidase for Mucopolysaccharidosis III (Sanfilippo)

Syndrome) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate SGSH for Mucopolysaccharidosis Type IIIA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JR-441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYSSAF-302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rebisufligene etispavovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme to Replace Sulphamidase for Mucopolysaccharidosis III (MPS III)  
(Sanfilippo Syndrome) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or  
Sulphamidase or SGSH or EC 3.10.1.1) - Dormant Products

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or  
Sulphamidase or SGSH or EC 3.10.1.1) - Discontinued Products

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or  
Sulphamidase or SGSH or EC 3.10.1.1) - Product Development Milestones

Featured News & Press Releases

Feb 15, 2021: Lysogene reports LYS-SAF302 biomarker data presented at the  
WORLDSymposium 2021

Feb 12, 2021: New positive interim data on ABO-102 presented at WORLDSymposium

Feb 02, 2021: Abeona Therapeutics announces clinical investigator webinar to review  
ABO-102 Clinical Data presented at the 17th Annual WORLDSymposium

Dec 28, 2020: Lysogene reports positive biomarker data with LYS-SAF302

Dec 21, 2020: Abeona Therapeutics announces acceptance of late-breaker abstracts

highlighting new clinical data for novel AAV-based gene therapies including rebisufligene etisparvovec at WORLDSymposium

Oct 15, 2020: Lysogene provides update on the AAVance clinical trial evaluating LYS-SAF302 in patients with MPS IIIA

Jun 05, 2020: Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA

Feb 25, 2020: Lysogene receives FDA fast track designation for LYS-SAF302 gene therapy in MPS IIIA

Feb 12, 2020: Abeona Therapeutics announces presentation on its MPS IIIA drug candidate ABO-102 at WORLDSymposium

Dec 20, 2019: Abeona Therapeutics receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA

Dec 18, 2019: Lysogene announces the publication of an article in the scientific journal "molecular therapy methods & clinical development" demonstrating the potential of its drug candidate LYS-SAF302

Oct 21, 2019: Abeona Therapeutics announces presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress

Jul 25, 2019: Abeona Therapeutics announces positive interim data from the ABO-102 phase 1/2 gene therapy clinical trial in MPS IIIA

Jul 25, 2019: Abeona Therapeutics announces positive interim data from the ABO-102 phase 1/2 gene therapy clinical trial in MPS IIIA

Jun 11, 2019: Lysogene announces first European patient treated in AAVance, Phase 2/3 clinical trial investigating LYS-SAF302, a gene therapy for the treatment of MPS IIIA (Sanfilippo Syndrome Type A)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Abeona Therapeutics Inc, 2021

Pipeline by Amicus Therapeutics Inc, 2021

Pipeline by ArmaGen Inc, 2021

Pipeline by Denali Therapeutics Inc, 2021

Pipeline by Esteve Pharmaceuticals SA, 2021

Pipeline by JCR Pharmaceuticals Co Ltd, 2021

Pipeline by Lysogene SAS, 2021

Pipeline by Tega Therapeutics Inc, 2021

Dormant Projects, 2021

Discontinued Products, 2021

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021



## I would like to order

Product name: N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/N6B71FA45F89EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N6B71FA45F89EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970